/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

Aclaris Therapeutics Inc Share Price Today: Live Updates & Key Insights

Aclaris Therapeutics Inc share price today is $3.62, up -1.34%. The stock opened at $3.765 against the previous close of $3.74, with an intraday high of $3.78 and low of $3.6.

Aclaris Therapeutics Inc Share Price Chart

style
pb-0

Aclaris Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

Aclaris Therapeutics Inc Share Price Performance

$3.62 -0.0134(-1.34%) ACRS at 23 Mar 2026 11:52 AM Biotechnology
Lowest Today 3.6
Highest Today 3.78
Today’s Open 3.765
Prev. Close 3.74
52 Week High 4.89
52 Week Low 1.05
Day’s Range: Low 3.6 High 3.78
52-Week Range: Low 1.05 High 4.89
1 day return -
1 Week return -1.46
1 month return +13.71
3 month return +20.0
6 month return +90.69
1 year return +116.42
3 year return -53.23
5 year return -86.65
10 year return -

Aclaris Therapeutics Inc Institutional Holdings

BML Capital Management LLC 11.77

Vivo Capital, LLC 7.34

Vanguard Group Inc 5.37

BlackRock Inc 4.70

Rock Springs Capital Management LP 3.68

Morgan Stanley - Brokerage Accounts 3.37

Decheng Capital LLC 3.34

Adage Capital Partners Gp LLC 2.78

Vanguard Total Stock Mkt Idx Inv 2.62

Geode Capital Management, LLC 1.98

Acadian Asset Management LLC 1.92

iShares Russell 2000 ETF 1.85

D. E. Shaw & Co LP 1.73

Palo Alto Investors, LLC 1.29

JPMorgan Chase & Co 1.25

Logos Global Management LP 1.24

Connor Clark & Lunn Inv Mgmt Ltd 1.18

Ameriprise Financial Inc 1.06

Citadel Advisors Llc 1.00

Renaissance Technologies Corp 0.93

State Street Corp 0.92

Vanguard Institutional Extnd Mkt Idx Tr 0.91

Millennium Management LLC 0.87

Xtrackers S&P 500 Swap ETF 1C 0.76

Fidelity Small Cap Index 0.75

iShares Russell 2000 Value ETF 0.66

iShares Biotechnology ETF 0.57

Vanguard Strategic Small-Cap Equity Inv 0.49

Fidelity Extended Market Index 0.43

Vanguard Russell 2000 ETF 0.36

iShares Core S&P Total US Stock Mkt ETF 0.31

State St Russell Sm/Mid Cp® Indx SL Cl I 0.28

State St Russell Sm Cap® Indx SL Cl I 0.26

JPMorgan Small Cap Value I 0.25

Vanguard VIF Small Co Gr 0.23

Blackrock Extended Mkt Fund CF 0.22

iShares Micro-Cap ETF 0.20

Goldman Sachs Small Cp Val Insghts Instl 0.20

Acuitas US Microcap Strategy 0.19

Extended Equity Market Fund K 0.19

Aclaris Therapeutics Inc Market Status

Strong Buy: 3

Buy: 2

Hold: 1

Sell: 0

Strong Sell: 0

Aclaris Therapeutics Inc Fundamentals

Market Cap 446.81 M

PB Ratio 4.3933

PE Ratio 0.0

Enterprise Value 362.12 M

Total Assets 160.46 M

Volume 2195789

Aclaris Therapeutics Inc Company Financials

Annual Revenue FY23:31249000 31.2M, FY22:29752000 29.8M, FY21:6761000 6.8M, FY20:6482000 6.5M, FY19:4227000 4.2M

Annual Profit FY23:13168000 13.2M, FY22:17792000 17.8M, FY21:2048000 2.0M, FY20:1349000 1.3M, FY19:172000 0.2M

Annual Net worth FY23:-88481000 -88.5M, FY22:-88662000 -88.7M, FY21:-114281000 -114.3M, FY20:-51154000 -51.2M, FY19:-142850000 -142.9M

Quarterly Revenue Q3/2025:3299000 3.3M, Q2/2025:1777000 1.8M, Q1/2025:1455000 1.5M, Q3/2024:4346000 4.3M, Q2/2024:2766000 2.8M

Quarterly Profit Q3/2025:2761000 2.8M, Q2/2025:-73000 -0.1M, Q1/2025:949000 0.9M, Q3/2024:1938000 1.9M, Q2/2024:857000 0.9M

Quarterly Net worth Q3/2025:-14614000 -14.6M, Q2/2025:-15429000 -15.4M, Q1/2025:-15085000 -15.1M, Q3/2024:-7586000 -7.6M, Q2/2024:-10986000 -11.0M

About Aclaris Therapeutics Inc & investment objective

Company Information Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Organisation Biotechnology

Employees 69

Industry Biotechnology

CEO Dr. Neal S. Walker D.O., M.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow

Aclaris Therapeutics Inc FAQs

What is the share price of Aclaris Therapeutics Inc today?

The current share price of Aclaris Therapeutics Inc is $3.62.

Can I buy Aclaris Therapeutics Inc shares in India?

Yes, Indian investors can buy Aclaris Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy Aclaris Therapeutics Inc shares in India?

You can easily invest in Aclaris Therapeutics Inc shares from India by:

Can I buy fractional shares of Aclaris Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of Aclaris Therapeutics Inc?

Aclaris Therapeutics Inc has a market cap of $446.81 M.

In which sector does Aclaris Therapeutics Inc belong?

Aclaris Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in Aclaris Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of Aclaris Therapeutics Inc?

The PE ratio of Aclaris Therapeutics Inc is N/A and the PB ratio is 4.39.